DTIL - Company ID 0001357874
PRECISION BIOSCIENCES INC trades as DTIL. In its fiscal 2025 annual report the company posted revenue of $34.26M, down 50.1% from the prior year and net income of -$45.72M. This page tracks PRECISION BIOSCIENCES INC through 567 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 7 fiscal years PRECISION BIOSCIENCES INC's revenue grew from $10.88M to $34.26M, a compound annual growth rate of 17.8%. Net profit margin expanded from -423.0% to -133.4% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-27 |
| Major company event | 8-K | 2026-05-26 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Quarterly report | 10-Q | 2026-05-05 |
The largest companies sharing PRECISION BIOSCIENCES INC's SEC industry classification (biological products, (no diagnostic substances)).
PRECISION BIOSCIENCES INC reported revenue of $34.26M for fiscal year 2025, a decrease of 50.1% year over year.
In its latest fiscal year PRECISION BIOSCIENCES INC reported a net loss of $45.72M.